Compare TRTX & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRTX | OVID |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.4M | 562.5M |
| IPO Year | 2015 | 2017 |
| Metric | TRTX | OVID |
|---|---|---|
| Price | $6.24 | $2.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $9.54 | $6.00 |
| AVG Volume (30 Days) | 1.4M | ★ 1.6M |
| Earning Date | 10-26-2026 | 11-11-2026 |
| Dividend Yield | ★ 16.41% | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.31 | N/A |
| P/E Ratio | $30.71 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $5.57 | $1.18 |
| 52 Week High | $9.37 | $3.11 |
| Indicator | TRTX | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 46.95 |
| Support Level | $5.57 | $2.09 |
| Resistance Level | $8.74 | $2.44 |
| Average True Range (ATR) | 0.21 | 0.17 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 87.59 | 47.32 |
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.